Regeneron's stock climbs 4% as analyst look past earnings miss to focus on pipeline
Regeneron Pharmaceuticals Inc REGN
News
-
Regeneron Pharmaceuticals 1Q Revenue Declines Amid Lower EYLEA Sales
Regeneron Reports First Quarter 2024 Financial and Operating Results
EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases
Regeneron Sets Crispr-Based Collaboration With Mammoth Biosciences
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)
REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Regeneron Stockholders and Encourages Investors to Contact the Firm
The Law Offices of Frank R. Cruz Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
Regeneron Pharmaceuticals on Track for Largest Percent Decrease Since June 2023 — Data Talk
Regeneron accused of 'fraudulent' drug-pricing reporting for eye drug Eylea
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024
FDA Rejects Regeneron's Odronextamab in Follicular, Diffuse Large B-cell Lymphoma
Regeneron Provides Update on Biologics License Application for Odronextamab
Kuehn Law Encourages Investors of Regeneron Pharmaceuticals, Inc. to Contact Law Firm
Intellia Therapeutics Ends Co-Development Agreement With Regeneron